02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 49.18
−3.00%Aug 27, 2026, 08:31 UTC
WuXi Biologics management raised its full-year 2026 revenue growth guidance to 20%-23% year-over-year on a constant currency basis, up from the previous 16%-20% guidance.
Source:Aug 25, 2026, 09:56 UTC
WuXi Biologics reported first-half results with revenue up 18.4% year-on-year to RMB 11.787 billion, gross profit up 28.1% to RMB 5.448 billion, and net profit up 5.8% to RMB 2.916 billion.
Aug 6, 2026, 23:32 UTC
Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.
Source:Jul 4, 2026, 11:52 UTC
Hong Kong-listed companies, led by Tencent Holdings, AIA Group, and Xiaomi Corporation, have conducted share buybacks totaling over 900 billion Hong Kong dollars year-to-date, with June 2026 reaching a monthly record of over 300 billion Hong Kong dollars.
Jun 18, 2026, 05:00 UTC
WuXi Biologics' Suzhou Biosafety Testing Center received its fourth EMA GMP certification, enabling 19 commercial products for the European market.
Source:Jun 5, 2026, 02:45 UTC
WuXi Biologics completed the topping-out of a drug product facility at its Singapore CRDMO Hub.
Source: